Spyre Therapeutics Inc. Market Cap ($7.87 Billion)
Market Cap & Net Worth: Spyre Therapeutics Inc. (SYRE)
Spyre Therapeutics Inc. market cap. Spyre Therapeutics Inc. (NASDAQ:SYRE) has a market capitalization of $7.87 Billion ($7.87 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2561 globally and #954 in its home market, demonstrating a 6.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spyre Therapeutics Inc.'s stock price $99.27 by its total outstanding shares 86841253 (86.84 Million). Also see cash efficiency ratio of Spyre Therapeutics Inc. for how efficiently the company converts equity into cash flow.
Spyre Therapeutics Inc. Market Cap History (2016–2026)
Spyre Therapeutics Inc. market cap history from 2016 to 2026. Data shows change from $9.44 Billion to $8.62 Billion (-8.16% CAGR). Check current stock price of Spyre Therapeutics Inc. for real-time trading data and today's change.
Index Memberships
Spyre Therapeutics Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.30% | #59 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.02% | #295 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.43% | #41 of 263 |
Weight: Spyre Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Spyre Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spyre Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SYRE year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2281.79x
Spyre Therapeutics Inc.'s market cap is 2281.79 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.44 Billion | $4.63 Million | -$21.70 Million | 2040.62x | N/A |
| 2017 | $11.75 Billion | $5.21 Million | -$27.24 Million | 2256.54x | N/A |
| 2018 | $16.26 Billion | $3.89 Million | -$44.35 Million | 4182.36x | N/A |
| 2021 | $10.31 Billion | $18.74 Million | -$65.80 Million | 550.32x | N/A |
| 2022 | $976.96 Million | $2.33 Million | -$83.81 Million | 419.48x | N/A |
| 2023 | $1.87 Billion | $886.00K | -$338.79 Million | 2109.28x | N/A |
| 2024 | $2.02 Billion | $886.00K | -$208.02 Million | 2281.79x | N/A |
Competitor Companies of SYRE by Market Capitalization
Companies near Spyre Therapeutics Inc. in the global market cap rankings as of November 4, 2026. Also see SYRE total assets for a full breakdown of the balance sheet.
Key companies related to Spyre Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Spyre Therapeutics Inc. (2016–2026)
Market capitalization of Spyre Therapeutics Inc. from 2016 to today. Between 2016 and today, Spyre Therapeutics Inc.'s market cap moved from $9.44 Billion to $ 8.62 Billion, with a yearly change of -8.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.62 Billion | +203.02% |
| 2025 | $2.84 Billion | +40.72% |
| 2024 | $2.02 Billion | +8.18% |
| 2023 | $1.87 Billion | +91.29% |
| 2022 | $976.96 Million | -90.53% |
| 2021 | $10.31 Billion | -39.64% |
| 2020 | $17.09 Billion | +3.01% |
| 2019 | $16.59 Billion | +2.00% |
| 2018 | $16.26 Billion | +38.45% |
| 2017 | $11.75 Billion | +24.37% |
| 2016 | $9.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Spyre Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.87 Billion USD |
| MoneyControl | $7.87 Billion USD |
| MarketWatch | $7.87 Billion USD |
| marketcap.company | $7.87 Billion USD |
| Reuters | $7.87 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more